United Therapeutics Corporation
1110 Spring Street
254 articles with United Therapeutics Corporation
United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
United Therapeutics Corporation announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018.
CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplant
Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities
United Therapeutics Corporation and MannKind Corporation today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.
United Therapeutics Corporation announced today that it will host Science Day 2018 in New York City on Monday, September 24th, beginning at approximately 10:00 A.M. Eastern Time and ending at approximately 4:00 P.M. Eastern Time.
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments
Correvio Pharma Corp. today highlighted that United Therapeutics (NASDAQ: UTHR) has completed its acquisition of SteadyMed Ltd., Correvio's partner and the licensor of Trevyent®.
MannKind Corporation, based in Westlake Village, California, and United Therapeutics, located in Silver Spring, Maryland, signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil.
United Therapeutics Corporation today announced that it has closed the merger of SteadyMed Ltd. with a subsidiary of United Therapeutics.
United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso
United Therapeutics Corporation announced today that it has entered into a Settlement Agreement with Watson Laboratories, Inc.
United Therapeutics Corporation announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its primary endpoint of delayed time to first clinical worsening event.
United Therapeutics Corporation announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the 2018 Wedbush PacGrow Healthcare Conference in New York City.
United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2018.
United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin® (ISR).
United Therapeutics Corporation To Report Second Quarter 2018 Financial Results Before The Market Opens On Wednesday, August 1, 2018
United Therapeutics Corporation announced that it will report its second quarter 2018 financial results before the market opens on Wednesday, August 1, 2018.
The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed's shareholders.
Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.
United Therapeutics And XVIVO Perfusion Announce Collaboration To Reduce Organ Shortage Through Expansion Of Organ Evaluation Service
The use of XVIVO's ex-vivo lung perfusion technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc.
United Therapeutics Corporation announced its financial results for the first quarter ended March 31, 2018.
United Therapeutics Corporation and SteadyMed Ltd. announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®.